CA2666981A1 - Recepteurs de tnf solubles et leur utilisation pour le traitement de maladies - Google Patents

Recepteurs de tnf solubles et leur utilisation pour le traitement de maladies Download PDF

Info

Publication number
CA2666981A1
CA2666981A1 CA002666981A CA2666981A CA2666981A1 CA 2666981 A1 CA2666981 A1 CA 2666981A1 CA 002666981 A CA002666981 A CA 002666981A CA 2666981 A CA2666981 A CA 2666981A CA 2666981 A1 CA2666981 A1 CA 2666981A1
Authority
CA
Canada
Prior art keywords
gene
seq
exon
tnfr2
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002666981A
Other languages
English (en)
Inventor
Peter L. Sazani
Maria Graziewicz
Ryszard Kole
Henrik Orum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Innovation Center Copenhagen AS
University of North Carolina at Chapel Hill
Ercole Biotech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2666981A1 publication Critical patent/CA2666981A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
CA002666981A 2006-10-20 2007-05-01 Recepteurs de tnf solubles et leur utilisation pour le traitement de maladies Abandoned CA2666981A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86235006P 2006-10-20 2006-10-20
US60/862,350 2006-10-20
USPCT/US2006/004365 2006-11-10
PCT/US2007/010556 WO2008051306A1 (fr) 2006-10-20 2007-05-01 Récepteurs de tnf solubles et leur utilisation pour le traitement de maladies

Publications (1)

Publication Number Publication Date
CA2666981A1 true CA2666981A1 (fr) 2008-05-02

Family

ID=40822966

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002666981A Abandoned CA2666981A1 (fr) 2006-10-20 2007-05-01 Recepteurs de tnf solubles et leur utilisation pour le traitement de maladies

Country Status (4)

Country Link
EP (1) EP2089521A1 (fr)
AU (1) AU2007309650A1 (fr)
CA (1) CA2666981A1 (fr)
WO (1) WO2008051306A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1282699B1 (fr) 2000-05-04 2012-11-21 Sarepta Therapeutics, Inc. Composition anti-sens a region d'epissage et methode associee
EP1713332A4 (fr) 2004-01-23 2010-08-18 Avi Biopharma Inc Oligomeres antisens et methodes destinees a induire la tolerance immunitaire et l'immunosuppression
ES2852549T3 (es) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
CA2684724A1 (fr) * 2007-05-01 2008-11-06 Santaris Pharma A/S Oligomeres permutant l'epissage pour la superfamille des recepteurs au tnf et leur utilisation dans le traitement de maladies
US9364495B2 (en) 2009-10-20 2016-06-14 Roche Innovation Center Copenhagen A/S Oral delivery of therapeutically effective LNA oligonucleotides
US8722615B2 (en) 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
WO2012096960A2 (fr) 2011-01-10 2012-07-19 The Regents Of The University Of Michigan Inhibiteur du facteur de cellules souches
US20150018408A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
WO2012170938A1 (fr) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions et procédés pour augmenter la demi-vie sérique
WO2013001372A2 (fr) 2011-06-30 2013-01-03 University Of Oslo Procédés et compositions pour inhiber l'activation des lymphocytes t régulateurs
WO2013005108A1 (fr) 2011-07-06 2013-01-10 Sykehuset Sorlandet Hf Traitement ayant pour cible egfr
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
MX363068B (es) 2012-11-15 2019-03-07 Roche Innovation Ct Copenhagen As Conjugados de oligonucleotido.
EP2935333A1 (fr) 2012-12-21 2015-10-28 Sykehuset Sorlandet HF Thérapie ciblée contre l'egfr de troubles neurologiques et de la douleur
CA2893801A1 (fr) 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Conjugues glucidiques d'oligonucleotides d'acides nucleiques bloques
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
EP3374399A1 (fr) 2015-11-11 2018-09-19 Opi Vi- IP Holdco LLC Composition et méthodes pour anticorps anti-tnfr2
CN112921046A (zh) * 2021-02-24 2021-06-08 上海市第十人民医院 一种可溶性人肿瘤坏死因子ⅱ型受体蛋白的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07504203A (ja) * 1992-09-15 1995-05-11 イミュネックス・コーポレーション 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法
JP2002539136A (ja) * 1999-03-11 2002-11-19 グリフォン サイエンシーズ 可溶性膜タンパク質受容体ドメイン類の化学合成と使用
KR101789603B1 (ko) * 2005-11-10 2017-11-21 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Ｔｎｆ 수퍼패밀리 수용체에 대한 스플라이스 스위칭올리고머 및 염증성 질환 치료용 약제학적 조성물

Also Published As

Publication number Publication date
WO2008051306A1 (fr) 2008-05-02
AU2007309650A8 (en) 2009-11-26
AU2007309650A1 (en) 2008-05-02
EP2089521A1 (fr) 2009-08-19
WO2008051306A8 (fr) 2009-10-01

Similar Documents

Publication Publication Date Title
US20210363222A1 (en) Soluble TNF Receptors and Their Use in Treatment of Disease
CA2666981A1 (fr) Recepteurs de tnf solubles et leur utilisation pour le traitement de maladies
AU2021204434A1 (en) Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
US20170015697A1 (en) Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
KR101789603B1 (ko) Ｔｎｆ 수퍼패밀리 수용체에 대한 스플라이스 스위칭올리고머 및 염증성 질환 치료용 약제학적 조성물
AU2022200560A1 (en) Soluble tnf receptors and their use in treatment of disease
AU2020213269A1 (en) Soluble tnf receptors and their use in treatment of disease
US20190359986A1 (en) Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20170822